Producing Monoclonal Antibody Patents (Class 435/70.21)
-
Patent number: 7915004Abstract: Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.Type: GrantFiled: April 27, 2005Date of Patent: March 29, 2011Assignee: Farma Development S.r.l.Inventors: Alberto Mantovani, Giuseppe Peri
-
Patent number: 7915389Abstract: An anti-acharan sulfate antibody, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The anti-acharan sulfate antibody can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to acharan sulfate.Type: GrantFiled: April 27, 2007Date of Patent: March 29, 2011Assignee: Seikagaku CorporationInventors: Kiyoshi Suzuki, Takeshi Ishimaru, Koji Yamamoto, Yeong Shik Kim
-
Patent number: 7910333Abstract: The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes.Type: GrantFiled: January 27, 2010Date of Patent: March 22, 2011Assignee: Elan Pharmaceuticals, Inc.Inventors: Tamie Chilcote, Robin Barbour
-
Patent number: 7910703Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: April 28, 2008Date of Patent: March 22, 2011Assignee: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber
-
Patent number: 7906297Abstract: The invention discloses two novel phosphorylation sites in human ATR kinase, serine 428 (Ser428) and serine 2317 (Ser2317) respectively, and provides reagents, including antibodies and AQUA peptides, that selectively bind to and/or detect ATR only when phosphorylated at one or more of these respective sites, but do not bind to ATR when not phosphorylated at these respective sites. Also provided are methods for determining the phosphorylation of ATR kinase in a biological sample, by using a detectable reagent that binds to ATR only when phosphorylated at Ser428 and/or Ser2317. Kits comprising the ATR (Ser428, Ser2317)-specific reagents of the invention are also provided.Type: GrantFiled: July 17, 2006Date of Patent: March 15, 2011Assignee: Cell Signaling Technology, Inc.Inventors: Mark Livingstone, Hong Ruan, Robert Polakiewicz
-
Patent number: 7897733Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monoclonal antibody.Type: GrantFiled: November 14, 2005Date of Patent: March 1, 2011Assignee: Pfizer, Inc.Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain
-
Patent number: 7893217Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.Type: GrantFiled: October 30, 2007Date of Patent: February 22, 2011Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
-
Patent number: 7892770Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.Type: GrantFiled: August 24, 2007Date of Patent: February 22, 2011Assignees: Van Andel Research Institute, Fred Hutchinson Cancer Research CenterInventors: Boliang Cao (Brian), George F. Vande Woude, Beatrice S. Knudsen
-
Patent number: 7887804Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.Type: GrantFiled: October 30, 2007Date of Patent: February 15, 2011Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
-
Patent number: 7887799Abstract: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.Type: GrantFiled: November 13, 2008Date of Patent: February 15, 2011Assignee: Amgen Inc.Inventors: Arlen Thomason, Benxian Liu
-
Patent number: 7888485Abstract: The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an effective amount of the antibodies described herein. The present invention also provides for methods of making the neutralizing antibodies described herein.Type: GrantFiled: March 26, 2004Date of Patent: February 15, 2011Assignee: Georgetown UniversityInventors: J. Yun Tso, Anton Wellstein, Debra Chao
-
Patent number: 7888479Abstract: The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.Type: GrantFiled: November 25, 2003Date of Patent: February 15, 2011Assignee: Biogen Idec Ma Inc.Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Ellen Garber, Carl Reid, Jose W. Saldanha, Herman Van Vlijmen
-
Publication number: 20110033467Abstract: The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.Type: ApplicationFiled: February 19, 2009Publication date: February 10, 2011Inventors: Valerie Wittamer, J. F. Mirjolet, Isabelle Migeotte, David Communi, Alberto Mantovani, Marisa Vulcano, Jean-Denis Franssen, Stephane Brezillon, Michel Detheux, Gilbert Vassart, Marc Parmentier, Emmanuel Le Poul, Cecile Loison, Frederic Ooms, Silvano Sozzani
-
Patent number: 7884198Abstract: The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.Type: GrantFiled: December 23, 2008Date of Patent: February 8, 2011Assignees: The Henry M. Jackon Foundation for the Advancement of Military Medicine, Altor Bioscience CorporationInventors: Gerald Walter Fischer, Richard F. Schuman, Hing Wong, Jeffrey R. Stinson
-
Patent number: 7879323Abstract: The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides.Type: GrantFiled: November 13, 2008Date of Patent: February 1, 2011Assignee: Amgen Inc.Inventors: Arlen Thomason, Benxian Liu
-
Patent number: 7872102Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.Type: GrantFiled: August 23, 2006Date of Patent: January 18, 2011Assignee: Eli Lilly and CompanyInventors: Catherine Brautigam Beidler, Stuart Willis Bright, Craig Duane Dickinson, Kristine Kay Kikly, David Matthew Marquis, Alain Philippe Vasserot
-
Patent number: 7867725Abstract: The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis.Type: GrantFiled: October 30, 2007Date of Patent: January 11, 2011Assignees: Maine Medical Center, University of Maine System BoardInventors: Lucy Liaw, Ah-Kau Ng
-
Publication number: 20110002937Abstract: This invention relates to a novel hybridoma strategy that uses CD27+ B cells cultured in vitro to induce IgM to IgG class switch prior to fusion with a fusion partner. Hybridomas resulting from the fusion between CD27+ B cells and a fusion partner cell line and antibodies secreted from the hybridomas are included in the invention.Type: ApplicationFiled: January 28, 2009Publication date: January 6, 2011Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Scott K. Dessain, Sharad P. Adekar
-
Patent number: 7863019Abstract: There are disclosed Interleukin-15 Receptor (IL-15R) proteins, DNAs and expression vectors encoding IL-15R, and processes for producing IL-15R as products of recombinant cell cultures.Type: GrantFiled: February 16, 2007Date of Patent: January 4, 2011Assignee: Immunex CorporationInventors: Dirk M. Anderson, Judith G. Giri
-
Publication number: 20100331206Abstract: Pregnancy-associated glycoproteins (PAGs) are structurally related to the pepsins, thought to be restricted to the hoofed (ungulate) mammals and characterized by being expressed specifically in the outer epithelial cell layer (chorion/trophectoderm) of the placenta. By cloning expressed genes from ovine and bovine placental cDNA libraries, the inventors estimate that cattle, sheep, and most probably all ruminant Artiodactyla, possess possibly 100 or more PAG genes, many of which are placentally expressed. The PAGs are highly diverse in sequence, with regions of hypervariability confined largely to surface-exposed loops. Selected PAG that are products of the invasive binucleate cells, expressed highly in early pregnancy at the time of trophoblast invasion and expressed weakly, if at all, in late gestation are useful in the early diagnosis of pregnancy. In a preferred embodiment, the invention relates to immunoassays for detecting these PAGs.Type: ApplicationFiled: June 28, 2010Publication date: December 30, 2010Inventors: Robert Michael Roberts, Jonathan Andrew Green, Sancai Xie
-
Patent number: 7858091Abstract: Using the proteins of the present invention, DNAs encoding the proteins, and antibodies recognizing the proteins, detection methods for diseases relating to the novel insulin-like growth factor binding proteins of the present invention, as well as diagnostic agents, preventive agents, and therapeutic agents for diseases relating to the proteins of the present invention can be provided.Type: GrantFiled: January 11, 2008Date of Patent: December 28, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kazuya Yamano, Susumu Sekine, Mitsuo Satoh, Toshio Ota, Akiko Furuya, Kenji Shibata, Yuki Kobayashi, Miho Takebayashi, Yusuke Nakamura, Sumio Sugano
-
Patent number: 7854930Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR.Type: GrantFiled: July 27, 2005Date of Patent: December 21, 2010Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia
-
Patent number: 7850963Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: April 3, 2007Date of Patent: December 14, 2010Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth Wager
-
Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
Patent number: 7851601Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.Type: GrantFiled: December 8, 2008Date of Patent: December 14, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki -
Patent number: 7846692Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to HE4. Monoclonal antibodies having the binding characteristics of an HE4 antibody of the invention are further provided. Hybridoma cell lines that produce an HE4 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed HE4 monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an HE4 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.Type: GrantFiled: March 7, 2008Date of Patent: December 7, 2010Assignee: Tripath Imaging, Inc.Inventors: Robert L. Cheek, Timothy J. Fischer, John W. Groelke
-
Patent number: 7846435Abstract: The invention provides humanized antibodies that specifically bind to, and preferably, neutralize, verotoxin II (VT2). The antibodies are useful for treating patients suffering from, or at risk of suffering, toxic effects of verotoxin.Type: GrantFiled: May 19, 1999Date of Patent: December 7, 2010Assignees: Teijin Limited, PDL Biopharma, Inc.Inventors: Yoh-Ichi Matsumoto, Atsuchi Imaizumi, Tsuyoshi Kimura, Tae Takeda, Yoshifumi Takeda, legal representative, Man Sung Co, Maximiliano Vasquez
-
Patent number: 7842500Abstract: An antibody which reacts with N-acetylheparosan and heparan sulfate that is derived from bovine kidney but does not substantially react with heparan sulfate derived from a murine Engelbreath-Holm-Swarn tumor tissue, the antibody being produced with a hybridoma which is prepared using a substance composed of a protein and N-acetylheparosan bound to the protein.Type: GrantFiled: March 31, 2006Date of Patent: November 30, 2010Assignee: Seikagaku CorporationInventors: Kiyoshi Suzuki, Takeshi Ishimaru, Koji Yamamoto
-
Patent number: 7842513Abstract: This invention provides methods and compositions for testing for pregnancy and non-pregnancy in ungulates and non-hoofed ruminates. The tests provided by this invention are useful during a time that coincides with the estrus cycle during which breeding occurs or the first estrus cycle after breeding of a non-pregnant animal. The tests provided by this invention are useful in estrus and ovulation synchronization programs, with pregnancy testing useful at a time allowing for resynchronization of non-pregnant animals within the first estrus cycle. The tests provided by this invention assay for the presence, absence, or level of a selected IFN-?-induced protein in a sample from a female animal. The tests of this invention are useful for testing cells, blood, plasma, serum, cells, milk, nasal secretions, ocular secretions, vaginal secretions, urine, and saliva samples. The tests provided by this invention are immunoassays.Type: GrantFiled: May 2, 2003Date of Patent: November 30, 2010Assignees: AspenBio Pharma, Inc., University of WyomingInventors: Mark Colgin, Diane Newman, Cathy Landmann, Jay W. Roth, Roger Hurst, Thomas R. Hansen, Kathleen Jeanette Austin
-
Patent number: 7838247Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: GrantFiled: August 20, 2007Date of Patent: November 23, 2010Assignees: HSC Research and Development Limited Partnership, The Governing Council of the University of TorontoInventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Patent number: 7834155Abstract: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.Type: GrantFiled: August 29, 2005Date of Patent: November 16, 2010Assignee: Immunogen Inc.Inventors: Gillian Payne, Philip Chun, Daniel J. Tavares
-
Publication number: 20100285017Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer treatment, and for drug development.Type: ApplicationFiled: February 7, 2010Publication date: November 11, 2010Inventors: Christian Rohlff, Jonathan Alexander Terrett
-
Patent number: 7829294Abstract: The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an A?-chain of the soluble fibrin formed through thrombin digestion of fibrinogen. The present invention is also directed to a hybridoma which produces the antibody, an immunological assay method employing the antibody, and a method for evaluating hypercoagulability in a test sample by measuring the soluble fibrin level in the sample with the assay method. Through employment of the monoclonal antibody of the present invention, soluble fibrin on which plasmin has not acted, which reflects exclusively initial hypercoagulability, can be specifically detected.Type: GrantFiled: December 27, 2005Date of Patent: November 9, 2010Assignee: Daiichi Pure Chemicals Co., Ltd.Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Osamu Miyazaki, Kyoko Tanaka, Akiko Suzuki
-
Patent number: 7820410Abstract: The invention relates to (glyco-) proteins, in particular monoclonal antibodies, which have an immunoreactivity of >81%, preferably >90%. The inventive monoclonal antibodies are produced using a fluidized bed reactor in conjunction with a conventional protein-chemical purification method or preferably with a purification method involving less column chromatography. The monoclonal antibodies thus produced are suitable, in gamma-irradiated form, e.g. Tc-99m labeled, for the in vivo diagnosis of inflammatory diseases and bone marrow metastases. In alpha- or beta-irradiated form, e.g. astatine or Re-188 or Y-90 labeled form, the inventive monoclonal antibodies can be used, for example, in the treatment of leukemia.Type: GrantFiled: August 1, 2007Date of Patent: October 26, 2010Assignee: Scintec Diagnostics GmbHInventors: Ivan Benes, Silke Thomsen-Bosslet
-
Patent number: 7811770Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.Type: GrantFiled: December 22, 2006Date of Patent: October 12, 2010Assignee: Roche Diagnostics Operations, Inc.Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
-
Patent number: 7807415Abstract: The invention provides a method of producing a stable lymphocyte culture and methods of producing monoclonal antibodies.Type: GrantFiled: August 23, 2006Date of Patent: October 5, 2010Assignee: IQ Therapeutics BVInventors: Herman Groen, Hans H. Westra
-
Patent number: 7807380Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.Type: GrantFiled: December 5, 2006Date of Patent: October 5, 2010Assignee: Roche Diagnostics Operations, Inc.Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
-
Antibodies and methods for generating genetically altered antibodies with enhanced effector function
Patent number: 7807416Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production. The invention also provides methods for increasing the effector function of monoclonal antibodies and monoclonal antibodies with increased effector function.Type: GrantFiled: October 15, 2008Date of Patent: October 5, 2010Assignee: Morphotek, Inc.Inventors: Luigi Grasso, Nicholas C. Nicolaides, Howard Sands, Philip M. Sass -
Patent number: 7803915Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: September 8, 2004Date of Patent: September 28, 2010Assignee: Genentech, Inc.Inventors: Belinda Cairns, Ruihuan Chen, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen, Heidi S. Phillips, Paul Polakis, Susan D. Spencer, Victoria Smith, P. Mickey Williams, Thomas D. Wu, Zemin Zhang, Chie Sakanaka, Anan Chuntharapai, Chae Janeka Reed
-
Patent number: 7799327Abstract: This invention describes a method whereby human autoimmune antibodies are used as carrier compounds to deliver imaging agents and pharmaceutical drugs to the tumor in the human patient. These autoantibodies have the propensity to localize in necrotic areas of tumors but not in healthy normal tissues. By combining various pharmaceutical agents with these carrier proteins it is possible to localize these agents within the necrotic areas of tumors in cancer patients. The carrier proteins may be combined with a variety of imaging agents for detection and diagnosis of tumors, and/or with a variety of radioactive or cytotoxic compounds for cancer treatment.Type: GrantFiled: December 24, 2003Date of Patent: September 21, 2010Inventors: Henry John Smith, James Roger Smith
-
Patent number: 7794981Abstract: A process is provided for the production of an antibody or a fragment or functionalized fragment thereof using a transformed lower eukaryotic host containing an example DNA sequence encoding the antibody or (functionalized) fragment thereof, wherein the antibody or (functionalized) fragment thereof is derived from a heavy chain immunoglobulin of Camelidae and is devoid of light chains, and wherein the lower eukaryotic host is a mould, preferably belonging to the genera Aspergillus or Trichoderma, or a yeast, preferably belonging to the yeast genera Saccharomyces, Kluyveromyces, Hansenula, or Pichia. The heavy chain fragment can contain at least the whole variable domain. A complementary determining region (CDR) different from the CDR belonging to the natural antibody ex Camelidae can be grafted on the framework of the variable domain of the heavy chain immunoglobulin. The catalytic antibodies can be raised in Camelidae against transition state molecules.Type: GrantFiled: August 11, 2004Date of Patent: September 14, 2010Assignee: BAC IP B.V.Inventors: Raymond Hamers, Cecile Hamers-Casterman, Serge V. M. Muyldermans, Leon G. J. Frenken, Cornelis T Verrips
-
Publication number: 20100227335Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MMP-7. Monoclonal antibodies having the binding characteristics of an MMP-7 antibody of the invention and monoclonal antibodies that bind to an MMP-7 epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce an MMP-7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed MMP-7 monoclonal antibodies and for practicing the methods of the invention are further provided.Type: ApplicationFiled: March 5, 2010Publication date: September 9, 2010Applicant: Becton, Dickinson and CompanyInventors: Jeffrey P. Baker, Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
-
Publication number: 20100227343Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided.Type: ApplicationFiled: March 5, 2010Publication date: September 9, 2010Applicant: Becton, Dickinson and CompanyInventors: Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, John W. Groelke, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
-
Patent number: 7790863Abstract: The present invention relates to angiogenesis inhibiting molecules that are the monoclonal antibody H33 or fragments or derivatives thereof, to their use in the treatment of cancer, in particular the treatment of solid tumors and to therapeutic and diagnostic compositions comprising them. The invention relates in particular to humanized derivatives of H33 of human monoclonal antibodies having the specificity of H33.Type: GrantFiled: November 19, 2004Date of Patent: September 7, 2010Assignee: Merck Serono S.A.Inventors: Beat A. Imhof, Michel Aurrand-Lions
-
Patent number: 7790163Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, an methods of using the same in inflammation.Type: GrantFiled: April 27, 2007Date of Patent: September 7, 2010Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica Huber
-
Patent number: 7777017Abstract: The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.Type: GrantFiled: March 13, 2007Date of Patent: August 17, 2010Assignee: Biosynexus IncorporatedInventors: Jeffrey R. Stinson, Richard F. Schuman, James Jacob Mond, Andrew Lees, Gerald Walter Fischer
-
Patent number: 7776330Abstract: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.Type: GrantFiled: September 25, 2007Date of Patent: August 17, 2010Assignee: City of HopeInventors: Paul J. Yazaki, Mark A. Sherman, John E. Shively, Andrew A. Raubitschek, Anna M. Wu
-
Patent number: 7771969Abstract: The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognises an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen.Type: GrantFiled: August 12, 2004Date of Patent: August 10, 2010Assignee: Celltech R&D LimitedInventors: Alastair David Griffiths Lawson, Meryn Ruth Griffiths
-
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
Patent number: 7754450Abstract: The invention provides methods for generating high titers of high-affinity antibodies from hybridoma cells produced by fusing myeloma cells with in vitro immunized donor cells. The hybridoma cells or mammalian expression cells with cloned antibody genes from the hybridomas producing the high-affinity antibodies may be mismatch repair defective due to defects of endogenous mismatch repair subunits of through expression of a dominant negative allele of a mismatch repair gene which allows the hybridoma cell to be hypermutable, may be rendered hypermutable by chemical means, or may be naturally mismatch repair deficient. High-affinity antibodies and high titer producer cells producing antibodies may be prepared by the methods of the invention.Type: GrantFiled: November 14, 2003Date of Patent: July 13, 2010Assignee: Morphotek, Inc.Inventors: Luigi Grasso, Shaohong Liang, Nicholas C. Nicolaides, Philip M. Sass -
Patent number: 7750124Abstract: An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.Type: GrantFiled: September 28, 2007Date of Patent: July 6, 2010Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Fumiko Axelrod, Tim Hoey, Sanjeev Satyal
-
Patent number: 7750125Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.Type: GrantFiled: August 17, 2007Date of Patent: July 6, 2010Assignee: University of RochesterInventors: Maurice Zauderer, Elizabeth E. Evans